Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

Characteristic

Spain

n = 119

Other Countriesa

n = 907

Sex, n (%)

  

 Female

64 (53.8)

548 (60.4)

 Male

55 (46.2)

359 (39.6)

HAE type, n (%)

  

 HAE-1

114 (95.8)

838 (92.4)

 HAE-2

5 (4.2)

69 (7.6)

Median (IQR) age at first symptoms, y

15.0 (5.0–20.0)

12.0 (5.0–18.0)

Median (IQR) age at diagnosis, y

22.3 (13.6–36.0)

20.5 (12.6–32.9)

Median (IQR) time to diagnosis, yb

6.4 (1.0–18.3)

5.4 (0.2–17.0)

Median (IQR) age at enrollment, y

39.3 (27.2–50.4)

39.0 (27.5–51.8)

Median (IQR) age at data extract, y

45.0 (34.0–56.0)

44.0 (32.0–57.0)

Median (IQR) duration of follow-up in IOS, y

5.6 (1.2–7.0)

2.4 (0.4–4.9)

  1. HAE-1/2 HAE due to C1 inhibitor deficiency, IOS Icatibant Outcome Survey
  2. aAustralia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Sweden, and the United Kingdom
  3. bDefined as the difference between age at first symptoms and age at diagnosis
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us